文献速递乳腺癌

GeparOLA研究:新辅助紫杉醇/奥拉帕利对比紫杉醇/卡铂治疗HER2阴性且同源重组缺陷乳腺癌

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
PubMed 文献 · Ann Oncol · 2020-10-21

GeparOLA研究纳入107例HER2阴性且同源重组缺陷(HRD)的早期乳腺癌患者,随机接受紫杉醇+奥拉帕利(PO)或紫杉醇+卡铂(PCb)新辅助治疗,序贯EC方案。主要终点pCR率在PO组为55.1%(90%CI 44.5-65.3),PCb组为48.6%(90%CI 34.3-63.2)。研究未能排除PO组pCR≤55%的假设,但PO方案耐受性显著更优,值得进一步评估。

要点

  • PO方案pCR率55.1%,未达预设排除≤55%的统计学阈值
  • PO方案耐受性显著优于PCb方案
  • 亚组分析提示<40岁和HR+患者PO组pCR率更高

核心结论

  • GeparOLA研究未能排除PO组pCR率≤55%的假设,但PO方案耐受性显著更优,值得进一步评估。

研究设计与样本

  • 随机II期研究,2016年9月至2018年7月纳入107例未经治疗的HER2阴性早期乳腺癌且HRD患者,随机接受紫杉醇+奥拉帕利(PO,N=69)或紫杉醇+卡铂(PCb,N=37),序贯表柔比星/环磷酰胺(EC)。

主要发现

  • PO组pCR率为55.1%(90%CI 44.5%-65.3%),PCb组为48.6%(90%CI 34.3%-63.2%)。
  • 分层亚组分析显示,<40岁和HR+患者中PO组pCR率更高。
  • PO方案耐受性显著优于PCb方案。

关键数值与推荐

  • 主要终点pCR(ypT0/is ypN0)预设排除PO组≤55%的pCR率,采用双侧单组χ2检验。
  • 患者中位年龄47.0岁(范围25.0-71.0),cT1占36.2%、cT2占61.0%、cT3占2.9%,cN+占31.8%,组织学分级3级占86.8%,Ki-67>20%占89.6%,TNBC占72.6%,确认gBRCA1/2突变占56.2%。

临床怎么用

  • 对于HER2阴性且HRD的早期乳腺癌患者,紫杉醇+奥拉帕利新辅助方案耐受性优于含铂方案,尤其适用于<40岁和HR+患者,但需进一步研究确认其疗效。

局限性

  • 研究为II期随机试验,样本量较小(PO组69例,PCb组37例),主要终点采用单组χ2检验设计,统计效力有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy and toxicity of olaparib as combination therapy in early breast cancer (BC) patients with homologous recombinant deficiency (HRD) [score high and/or germline (g) or tumour (t) BRCA1/2 mutation] is not well described. GeparOLA (ClinicalTrials.gov, NCT02789332) investigated olaparib in combination with paclitaxel in HER2-negative early BC with HRD. PATIENTS AND METHODS: Patients with untreated primary HER2-negative cT2-cT4a-d or cT1c with either cN+ or pNSLN+ or cT1c and triple-negative breast cancer (TNBC) or cT1c and Ki-67>20% BC with HRD were randomised either to paclitaxel (P) 80 mg/m2 weekly plus olaparib (O) 100 mg twice daily for 12 weeks or P plus carboplatinum (Cb) area under the curve 2 weekly for 12 weeks, both followed by epirubicin/cyclophosphamide (EC). Stratification factors were hormone receptor (HR) status (HR+ versus HR-) and age (<40 versus ≥40 years). The primary endpoint was pathological complete response (pCR; ypT0/is ypN0). A two-sided one-group χ2-test was planned to exclude a pCR rate of ≤55% in the PO-EC arm. Secondary end points were other pCR definitions, breast conservation rate, clinical/imaging response, tolerability and safety. RESULTS: A total of 107 patients were randomised between September 2016 and July 2018; 106 (PO N = 69; PCb N = 37) started treatment. Median age was 47.0 years (range 25.0-71.0); 36.2% had cT1, 61.0% cT2, 2.9% cT3, and 31.8% cN-positive tumours; grade 3 tumours: 86.8%; Ki-67>20%: 89.6%; TNBC: 72.6%; confirmed gBRCA1/2 mutation: 56.2%. The pCR rate with PO was 55.1% [90% confidence interval (CI) 44.5% to 65.3%] versus PCb 48.6% (90% CI 34.3% to 63.2%). Analysis for the stratified subgroups showed higher pCR rates with PO in the cohorts of patients <40 years and HR+ patients. CONCLUSION: GeparOLA could not exclude a pCR rate of ≤55% in the PO arm. PO was significantly better tolerated and the combination merits further evaluation.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Fasching PA, Link T, Hauke J, et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol. 2020. PMID: 33098995. doi:10.1016/j.annonc.2020.10.471

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。